Renal Cell Carcinoma – Epidemiology Forecast to 2028

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, which is part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC is the most common type of kidney cancer in adults, and is responsible for approximately 90% of all cases in adults (Ljungberg et al., 2011). The condition is asymptomatic in its initial stages, and as a result, people with RCC are often in the advanced stages of the disease by the time it is discovered. The initial symptoms of RCC often include blood in the urine, flank pain, a mass in the abdomen or flank, weight loss, fever, hypertension (high blood pressure), night sweats, and a general feeling of being unwell. Kidney cancer is among the 10 most frequently occurring cancers in Western countries. Globally, about 270,000 cases of kidney cancer are diagnosed annually, and 116,000 people die from the disease each year (Ljungberg et al., 2011).
In 2018, there were 199,032 diagnosed incident cases of RCC in the 8MM. China had the most cases in the 8MM, with 60,699 cases, followed by the US with 57,241 cases. Spain had the lowest number of cases in the 8MM, with 5,232 cases. In 2018, there were 579,682 five-year diagnosed prevalent cases of RCC cancer in the 8MM. The US had the highest number of cases, with 199,238 cases, followed by China with 139,479 cases. Spain had the lowest number of prevalent cases in the 8MM, with 15,248 cases.

Scope

The Renal Cell Carcinoma Epidemiology Report and Model provide an overview of the risk factors and global trends of RCC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).

The report also includes a 10-year epidemiological forecast for the diagnosed incident cases of RCC, segmented by age (for ages 18 years and older) and sex. GlobalData epidemiologists also forecast the five-year diagnosed prevalent cases and 10-year diagnosed prevalent cases of RCC in the 8MM. Additionally, the report provides the RCC diagnosed incident cases, segmented by the stage at diagnosis (stage I, stage II, stage III, stage IV, with stage IV being further segmented by clear cell renal carcinoma, non-clear cell renal carcinoma, and papillary renal cell carcinoma), prognostic model (good risk, intermediate risk, and poor risk), and biomarkers (overexpression of epidermal growth factor receptor [EGFR], vascular endothelial growth factor [VEGF], and mammalian target of rapamycin [mTOR]) for the 8MM.

The RCC epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The RCC Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global RCC market.

Quantify patient populations in the global RCC market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups that present the best opportunities for RCC therapeutics in each of the markets covered.

Understand magnitude of RCC by stage at diagnosis and prognostic model, and biomarkers.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 RCC: Executive Summary

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods, Population

3.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC

3.4.4 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC by Stage at Diagnosis

3.4.5 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC by Prognostic Model

3.4.6 Forecast Assumptions and Methods, Diagnosed Incident Cases of RCC by Biomarkers

3.4.7 Forecast Assumptions and Methods, Five-Year and 10-Year Diagnosed Prevalent Cases of RCC

3.5 Epidemiological Forecast for RCC (2018–2028)

3.5.1 Diagnosed Incident Cases of RCC

3.5.2 Age-Specific Diagnosed Incident Cases of RCC

3.5.3 Sex-Specific Diagnosed Incident Cases of RCC

3.5.4 Diagnosed Incident Cases of RCC by Stage at Diagnosis

3.5.5 Diagnosed Incident Cases of RCC Stage IV by Prognostic Model

3.5.6 Diagnosed Incident Cases of RCC Stage IV by Biomarkers

3.5.7 Five-Year Diagnosed Prevalent Cases of RCC

3.5.8 10-Year Diagnosed Prevalent Cases of RCC

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of the Analysis

3.6.3 Strengths of the Analysis

4 Appendix

4.1 Bibliography

4.2 Abbreviations

4.3 About the Authors

4.3.1 Epidemiologist

4.3.2 Reviewers

4.3.3 Global Director of Therapy Analysis and Epidemiology

4.3.4 Global Head and EVP of Healthcare Operations and Strategy

4.4 About GlobalData

4.5 Contact Us

4.6 Disclaimer

Table

Table 1: Summary of Newly Added Data Types and Countries

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbidities for RCC

Table 4: RCC Clinical Stages at Diagnosis

Figures

Figure 1: 8MM, Diagnosed Incident Cases of RCC, Ages ≥18 Years, Both Sexes, N, 2018 and 2028

Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥18 Years, Both Sexes, N, 2018 and 2028

Figure 3: 8MM, Diagnosed Incidence of RCC, Men, Ages ≥18 Years, 2008–2028

Figure 4: 8MM, Diagnosed Incidence of RCC, Women, Ages ≥18 Years, 2008–2028

Figure 5: 8MM, Sources Used, Diagnosed Incident Cases of RCC

Figure 6: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Stage at Diagnosis

Figure 7: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Prognostic Model

Figure 8: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Biomarker (Overexpression of EGFR)

Figure 9: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Biomarker (Overexpression of VEGF)

Figure 10: 8MM, Sources Used, Diagnosed Incident Cases of RCC by Biomarker (Overexpression of mTOR)

Figure 11: 8MM, Sources Used, Five-Year and 10-Year Diagnosed Prevalent Cases of RCC

Figure 12: 8MM, Diagnosed Incident Cases of RCC, Ages ≥18 Years, Both Sexes, N, 2018

Figure 13: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N, 2018

Figure 14: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ≥18 Years, N, 2018

Figure 15: 8MM, Diagnosed Incident Cases of RCC by Stage at Diagnosis, Ages ≥18 Years, Both Sexes, N, 2018

Figure 16: 8MM, Diagnosed Incident Cases of RCC Stage IV by Prognostic Model, Ages ≥18 Years, Both Sexes, N, 2018

Figure 17: 8MM, Diagnosed Incident Cases of RCC Stage IV by Biomarkers, Ages ≥18 Years, Both Sexes, N, 2018

Figure 18: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Ages ≥18 Years, Both Sexes, N, 2018

Figure 19: 8MM, 10-Year Diagnosed Prevalent Cases of RCC, Ages ≥18 Years, Both Sexes, N, 2018

Frequently asked questions

Renal Cell Carcinoma – Epidemiology Forecast to 2028 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Renal Cell Carcinoma – Epidemiology Forecast to 2028 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Renal Cell Carcinoma – Epidemiology Forecast to 2028 in real time.

  • Access a live Renal Cell Carcinoma – Epidemiology Forecast to 2028 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.